within Pharmacolibrary.Drugs.ATC.A;

model A03FA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.23,
    Cl             = 0.013333333333333334,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002616666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cinitapride is a substituted benzamide with gastroprokinetic and antiemetic properties. It acts as an agonist at 5-HT4 and 5-HT1 receptors and antagonist at 5-HT2 receptors, facilitating gastrointestinal motility. It is used in the management of gastroesophageal reflux disease (GERD), functional dyspepsia, and other gastrointestinal motility disorders and is approved in some countries including India and Spain, but not widely approved in many others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult human subjects after oral administration.</p><h4>References</h4><ol><li><p>Robert, M, et al., &amp; Golor, G (2007). The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 35(7) 1149–1156. DOI:<a href=&quot;https://doi.org/10.1124/dmd.106.010835&quot;>10.1124/dmd.106.010835</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17437965/&quot;>https://pubmed.ncbi.nlm.nih.gov/17437965</a></p></li><li><p>Bushra, R, et al., &amp; Ahmed, K (2019). Stability and in vitro release kinetic studies of cinitapride (1mg) mouth dissolving tablets. <i>Pakistan journal of pharmaceutical sciences</i> 32(2 (Supplementary)) 793–798. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31103974/&quot;>https://pubmed.ncbi.nlm.nih.gov/31103974</a></p></li><li><p>Marcelín-Jiménez, G, et al., &amp; García-González, A (2017). Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial. <i>Bioanalysis</i> 9(6) 569–579. DOI:<a href=&quot;https://doi.org/10.4155/bio-2016-0210&quot;>10.4155/bio-2016-0210</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28225297/&quot;>https://pubmed.ncbi.nlm.nih.gov/28225297</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03FA08;
